Merck KGaA keeps building with 'superb business results'

4 March 2021

German science and technology company Merck KGaA (MRK: DE) has reported impressive sales and earnings figures in its latest quarterly and full-year 2020 financial results.

The group’s adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) in 2020 rose 18.6% to 5.2 billion euros ($6.27 billion), meeting average analyst expectations. For the fourth quarter, this figure was 1.2 billion euros, a rise of 3.3%.

"Our focus on innovation-driven specialty businesses is paying off"Group sales for the year rose by 8.6% to 17.5 billion euros, while for the fourth quarter they were 5% higher than in the same period of 2019.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK